Recent advances in the systemic therapy of cancer

被引：0

作者：

Harrington, J. ^{[1
]}

Evans, T. R. J. ^{[2
]}

机构：

[1] Beatson West Scotland Canc Ctr, Med Oncol, Glasgow, Lanark, Scotland

[2] Univ Glasgow, Ctr Oncol & Appl Pharmacol, Translat Canc Res, Glasgow, Lanark, Scotland

来源：

JOURNAL OF THE ROYAL COLLEGE OF PHYSICIANS OF EDINBURGH | 2009年 / 39卷 / 02期

关键词：

Angiogenesis; apoptosis; cell cycle regulation; cellular senescence; monoclonal antibodies; tyrosine kinase;

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

The current generation of anti-cancer agents, often referred to as molecularly targeted therapies, are based on exploiting our increasing understanding of the molecular and cellular basis of cancer development and progression. This review focuses on these therapies, particularly as many of the drugs concerned have received considerable attention in the popular media.

引用

页码：134 / 137

页数：4

共 13 条

[1] GROWTH-FACTORS AND CANCER [J].

AARONSON, SA .

SCIENCE, 1991, 254 (5035) :1146-1153

[2] Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. [J].

Druker, BJ ;

Talpaz, M ;

Resta, DJ ;

Peng, B ;

Buchdunger, E ;

Ford, JM ;

Lydon, NB ;

Kantarjian, H ;

Capdeville, R ;

Ohno-Jones, S ;

Sawyers, CL .

NEW ENGLAND JOURNAL OF MEDICINE, 2001, 344 (14) :1031-1037

[3]

Evans J., TREATMENT OF CANC, P75

[4] Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: A phase III trial-INTACT1 [J].

Giaccone, G ;

Herbst, RS ;

Manegold, C ;

Scagliotti, G ;

Rosell, R ;

Miller, V ;

Natale, RB ;

Schiller, JH ;

von Pawel, J ;

Pluzanska, A ;

Gatzemeier, M ;

Grous, J ;

Ochs, JS ;

Averbuch, SD ;

Wolf, MK ;

Rennie, P ;

Fandi, A ;

Johnson, DH .

JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (05) :777-784

[5] The hallmarks of cancer [J].

Hanahan, D ;

Weinberg, RA .

CELL, 2000, 100 (01) :57-70

[6] Inhibiting signal transduction: Recent advances in the development of receptor tyrosine kinase and Ras inhibitors [J].

Hao, D ;

Rowinsky, EK .

CANCER INVESTIGATION, 2002, 20 (03) :387-404

[7] The fundamental role of epigenetic events in cancer [J].

Jones, PA ;

Baylin, SB .

NATURE REVIEWS GENETICS, 2002, 3 (06) :415-428

[8] Sorafenib in advanced hepatocellular carcinoma [J].

Llovet, Josep M. ;

Ricci, Sergio ;

Mazzaferro, Vincenzo ;

Hilgard, Philip ;

Gane, Edward ;

Blanc, Jean-Frederic ;

Cosme de Oliveira, Andre ;

Santoro, Armando ;

Raoul, Jean-Luc ;

Forner, Alejandro ;

Schwartz, Myron ;

Porta, Camillo ;

Zeuzem, Stefan ;

Bolondi, Luigi ;

Greten, Tim F. ;

Galle, Peter R. ;

Seitz, Jean-Francois ;

Borbath, Ivan ;

Haussinger, Dieter ;

Giannaris, Tom ;

Shan, Minghua ;

Moscovici, Marius ;

Voliotis, Dimitris ;

Bruix, Jordi .

NEW ENGLAND JOURNAL OF MEDICINE, 2008, 359 (04) :378-390

[9] Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib [J].

Lynch, TJ ;

Bell, DW ;

Sordella, R ;

Gurubhagavatula, S ;

Okimoto, RA ;

Brannigan, BW ;

Harris, PL ;

Haserlat, SM ;

Supko, JG ;

Haluska, FG ;

Louis, DN ;

Christiani, DC ;

Settleman, J ;

Haber, DA .

NEW ENGLAND JOURNAL OF MEDICINE, 2004, 350 (21) :2129-2139

[10] Bevacizumab - current status and future directions [J].

Midgley, R ;

Kerr, D .

ANNALS OF ONCOLOGY, 2005, 16 (07) :999-1004

← 1 2 →